Genmab A/S (NASDAQ:GMAB) Hits New 12-Month High Following Analyst Upgrade

Genmab A/S Sponsored ADR (NASDAQ:GMAB)’s stock price reached a new 52-week high during trading on Tuesday after Guggenheim upgraded the stock from a neutral rating to a buy rating. Guggenheim now has a $43.00 price target on the stock. Genmab A/S traded as high as $28.86 and last traded at $28.87, with a volume of 183484 shares traded. The stock had previously closed at $28.60.

A number of other research analysts have also recently issued reports on GMAB. Zacks Research cut shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Wall Street Zen raised shares of Genmab A/S from a “hold” rating to a “buy” rating in a research report on Monday, July 28th. HC Wainwright lifted their price target on shares of Genmab A/S from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Friday, August 15th. Finally, Truist Financial lifted their price target on shares of Genmab A/S from $45.00 to $46.00 and gave the company a “buy” rating in a research report on Tuesday, July 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $40.00.

Institutional Trading of Genmab A/S

Large investors have recently made changes to their positions in the stock. Headlands Technologies LLC grew its stake in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after acquiring an additional 1,464 shares during the period. Osaic Holdings Inc. grew its position in Genmab A/S by 37.8% during the second quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after buying an additional 440 shares during the period. CWM LLC grew its position in Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after buying an additional 603 shares during the period. Caitong International Asset Management Co. Ltd grew its position in Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock valued at $38,000 after buying an additional 1,070 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in Genmab A/S by 124.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock valued at $44,000 after buying an additional 1,174 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Price Performance

The firm’s 50-day moving average is $24.53 and its 200-day moving average is $21.88. The company has a market capitalization of $18.43 billion, a P/E ratio of 14.44, a price-to-earnings-growth ratio of 1.67 and a beta of 0.93.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Genmab A/S has set its FY 2025 guidance at EPS. As a group, analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.